Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reviva Pharmaceuticals Hldg Inc (NQ: RVPH )

3.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184
Open 3.020
Bid (Size) 2.950 (29)
Ask (Size) 3.100 (7)
Prev. Close 3.020
Today's Range 3.020 - 3.020
52wk Range 2.670 - 9.250
Shares Outstanding 22,650,266
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks. 
Via InvestorPlace

Performance

YTD
-43.13%
-43.13%
1 Month
+6.34%
+6.34%
3 Month
-25.80%
-25.80%
6 Month
-18.60%
-18.60%
1 Year
-40.08%
-40.08%

More News

Read More
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Expert Ratings for Reviva Pharmaceuticals
Via Benzinga
Where Reviva Pharmaceuticals Stands With Analysts
Via Benzinga
Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data
Via Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
From Virtual Investor Conferences
Via GlobeNewswire
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
RedChip Launches 'Small Stocks, Big Money' Podcast
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
RedChip CEO Dave Gentry Invited to Join Forbes Business Council
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.